FDA Outlines Priorities For Next Five Years In Strategic Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency identifies four overarching priorities: advancing regulatory science and innovation; strengthening the global supply chain; strengthening compliance and enforcement activities; and addressing unmet public health needs.
You may also be interested in...
FDA Budget Issues Creep Into Strategic Priorities
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.